Product
NGM831 and NGM438 plus pembrolizumab
Aliases
NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®)
1 clinical trial
15 indications
Indication
Pancreatic CancerIndication
Breast CancerIndication
Stomach CancerIndication
Lung CancerIndication
Cervical CancerIndication
Squamous Cell Carcinoma of Head and NeckIndication
Bladder CancerIndication
Colorectal cancerIndication
Esophageal cancerIndication
Ovarian CancerIndication
Renal Cell CarcinomaIndication
Prostate CancerIndication
MelanomaIndication
MesotheliomaIndication
CholangiocarcinomaClinical trial
A Phase 1 Dose Escalation/Dose Finding Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2025-07-01